IMFINZI-based treatment before and after surgery reduced the risk of disease recurrence, progression events or death by 32% in ...
Results presented at AACR 2023 found that four times as many patients treated with Imfinzi plus chemotherapy before surgery achieved pathologic complete response versus those treated with neoadjuvant chemotherapy alone Positive results from the AEGEAN …